News Headlines

  1. FUJIFILM Diosynth Biotechnologies And Regeneron Sign A 10-Year U.S. Manufacturing Agreement Valued At Over $3B 4/22/2025

    FUJIFILM Diosynth Biotechnologies, a world-leading contract development and manufacturing organization (CDMO) for biologics, vaccines, and advanced therapies, today announced a 10-year manufacturing supply agreement, valued at over $3B, with Regeneron Pharmaceuticals, Inc. to provide U.S.-based production of its industry-leading biologic medicines, which treat millions of patients worldwide.

  2. CARBOGEN AMCIS Shanghai Site Awarded Drug Manufacturing License From Chinese NMPA 4/22/2025

    CARBOGEN AMCIS, a Switzerland-based pharmaceutical process development and Active Pharmaceutical Ingredient (API) manufacturing company is pleased to announce that its Shanghai facility has successfully obtained its first Drug Manufacturing License (DML) from China’s National Medical Products Administration (NMPA).

  3. Roche To Invest USD 50 Billion In Pharmaceuticals And Diagnostics In The United States Over The Next Five Years 4/22/2025

    Roche announced today that it will invest USD 50 billion into the United States of America in the next five years. These investments further strengthen Roche’s already significant US footprint with 13 manufacturing and 15 R&D sites across the Pharmaceutical and Diagnostics Divisions, and are expected to create more than 12,000 new jobs, including nearly 6,500 construction jobs, as well as 1,000 jobs at new and expanded facilities.

  4. Applied DNA's LineaRx Subsidiary Stands Ready To Support The Reshoring Of Drug Development And Manufacturing With U.S.-Produced Synthetic DNA 4/21/2025

    Applied DNA Sciences, Inc. (Applied DNA or the “Company”), a leader in PCR-based DNA technologies, today announced that LineaRx, Inc., the Company’s majority-owned subsidiary, has completed a long-term initiative to source critical input materials for its LineaDNA and LineaIVT platforms from U.S.-based suppliers.

  5. Rigaku And SPERA PHARMA Initiate Strategic Partnership To Advanced Pharmaceutical Development 4/17/2025

    Rigaku Corporation, a Group company of Rigaku Holdings Corporation (headquarters: Akishima, Tokyo; CEO: Jun Kawakami; hereinafter “Rigaku”), and SPERA PHARMA, Inc. (headquarters: Osaka; President & Representative Director: Keitaro Iwaki; hereinafter “SPERA PHARMA”) have initiated a strategic partnership aimed at accelerating and transforming pharmaceutical development by leveraging the two companies’ cutting-edge technologies and extensive expertise.

  6. ViroCell Manufactured A GMP Lentiviral Vector For UCL To Accelerate Research Into Prevention Of Relapse In Childhood Blood Cancer 4/17/2025

    ViroCell Biologics (“ViroCell” or the “Company”), a specialist viral vector Contract Development and Manufacturing Organisation (“CDMO”) for cell and gene therapy (CGT) clinical trials, announces the opening of a University College London (“UCL”) clinical trial to advance Professor Persis Amrolia’s innovative chimeric antigen receptor (CAR) T-cell therapy for relapsed paediatric acute lymphoblastic leukaemia (ALL).

  7. FesariusTherapeutics Announces Manufacturing Agreement For DermiSphere hDRT, The First Hydrogel Dermal Regeneration Template 4/17/2025

    FesariusTherapeutics Inc., a commercial-stage bioregenerative surgical company focused on delivering cutting-edge solutions for the wound care, reconstructive surgery and regenerative medicine markets, today announces it has entered into an exclusive, multi-year manufacturing and supply agreement with Regenity Biosciences ("Regenity"), the leading development and manufacturing partner of regenerative technologies for the medical device community.

  8. Thermo Fisher Scientific Opens Advanced Therapies Collaboration Center In Greater San Diego To Help Accelerate Cell Therapy Development 4/17/2025

    Thermo Fisher Scientific Inc., the world leader in serving science, today announced the grand opening of its Advanced Therapies Collaboration Center (ATxCC) in Carlsbad, Calif.

  9. Ritedose Adds Seventh Syntegon Packaging Line To Expand Single Vial Packaging Capabilities, Support Production Of New COPD Drug Ohtuvayre 4/16/2025

    Anticipating a rising need for individually wrapped vial medication manufacturing, The Ritedose Corporation, Inc. (Ritedose) is adding a seventh Syntegon packaging line to its state-of-the-art manufacturing facility that will double the company's capacity.

  10. Porton Advanced's End-To-End CDMO Solutions Accelerates IND Approval Of Tasly's Innovative Dual-Targeting CAR-T Therapy 4/16/2025

     April 12, 2025, Porton Advanced proudly announces its CDMO support for TASLY PHARMACEUTICAL CO., LTD's Innovative Dual-Targeting CAR-T Therapy, "P134 Cell Injection," which has received Investigational New Drug (IND) approval from China's National Medical Products Administration (NMPA) (Approval No.: 2025LP01030).